ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF

ALTERITY THERAPEUTICS LTD

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 28, 2026

$2.43−0.19 (-7.25%)

Close on Oct 19, 2026

ALTERITY THERAPEUTICS LTD cash flow statement

AnnualQuarterlyTTM

AUD USD

Millions of AUD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30
Stock-Based Compensation	4.49	0.98	0.88	0.97	1.51	–	–	–	–	–	–
Operating Cash Flow	-23	-11	-13	-20	-12	-17	-9.43	-14	-6.25	-5.87	-7.42
Capital Expenditures	0	0	-0.01	-0.01	-0.09	-0.01	-0.02	-0.01	-0.06	-0.03	0.00
Investing Cash Flow	–	-7.50	-0.01	-0.04	-0.09	-0.01	-0.02	-0.01	-0.02	-0.03	0.00
Financing Cash Flow	19	40	9.22	0.12	16	37	3.98	13	-0.11	-0.16	–
Foreign Exchange Rate Adjustments	0.05	-0.20	0.26	0.91	2.81	-0.43	0.26	0.40	-0.28	0.66	0.95
Free Cash Flow	-23	-11	-13	-20	-12	-17	-9.45	-14	-6.31	-5.89	-7.42
Income Taxes Paid	0.08	0.07	0.06	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: –

Financial strength

Current ratio: 14.52
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1182.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.